Lawmakers raised questions and concerns about the sale of genetic-testing company 23andMe during a hearing on Tuesday.

Twenty-seven states, including Illinois and Wisconsin, and the District of Columbia on Monday filed a lawsuit in bankruptcy ...

More than two dozen states, along with the District of Columbia, are suing biotechnology company 23andMe over plans to ...

Regeneron Pharmaceuticals just got a haircut from Wall Street, with JPMorgan Chase & Co. lowering its price target from $950 ...

We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. (REGN) on Notes From The Beauty Contest’s Substack. In ...

Intellectus Partners LLC recently doubled down on Regeneron Pharmaceuticals, upping its stake by 92.7% in Q1. The firm now ...

WASHINGTON — Twenty-seven states and the District of Columbia on Monday filed a lawsuit in bankruptcy court seeking to block ...

US biotech Regeneron and French drugmaker Sanofi are reviewing next steps for their experimental COPD therapy itepekimab ...

Regeneron’s stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after ...

For more comprehensive information about current price movements while Regeneron shares crash, please visit CDS.

Regneron stock crashed today following disappointing COPD trials data. Here's what makes REGN shares worth buying on the ...